LSI TOP2A (Orange)/CEP17 (Green)

« back

Probe location


Probe description

The TOP2A FISH kit is intended for the determination of TOP2A gene amplification in human tissues using fluorescence in situ hybridization (FISH).
The TOP2A FISH kit contains two directly labeled fluorescent DNA probes in hybridization buffer. The fluorochrome Orange labeled TOP2A probe covers the chromosome 17q21 region. The fluorochrome Green labeled chromosome enumeration CEP17 probe covers the chromosome 17p11.1-q11.1 region.
The TOP2A (DNA topoisomerase 2-alpha) gene encodes DNA topoisomerase II-alpha, which is involved in processes such as replication, transcription, chromosome condensation and chromatids separation. TOP2A amplification is frequent in breast cancers and occurs also with Her-2/neu amplification. TOP2A, Her-2/neu genes co-amplification can be a useful predictive marker of responsiveness to anthracycline based chemotherapy regiments.

FISH results

Normal cell (Fig.1a) shows 2 orange signals (TOP2A). An abnormal cell (Fig.1b) shows higher copy number of TOP2A gene.

A normal cell in FFPE tissue hybridized with LSI TOP2A (Orange)/CEP17 (Green) shows 2 orange signals of TOP2A gene and 2 green signals of chromosome 17. An abnormal cell in FFPE tissue hybridized with LSI TOP2A (Orange)/CEP17 (Green) shows a higher copy number of RARA gene and 2 green signals of chromosome 17.
a b

Figure. 1: Assessment of the copy number of TOP2A gene and copy number of chromozome 17 on FFPE tissue (breast cancer patient tissue).    
red LSI TOP2A 
green CEP17
a) 2 copies of TOP2A gene and 2 copies of chromosome 17.
b) 2 copies of chromosome 17 and higher copy number of TOP2A gene (amplificaton).



Catalogue number

Packing size


Information for use

LSI TOP2A (Orange)/CEP17 (Green)



upon request



  • Hurley LH: DNA and its associated processes as targets for cancer therapy. Nat Rev Cancer 2002; 2: 188-200. [fulltext]
  • Keith WN, Douglas F, Wishart GC, McCallum HM, George WD, Kaye SB, Brown R: Co-amplification of erbB2, topoisomerase II a and retinoic acid receptor a genes in breast cancer and allelic loss of topoisomerase I on chromosome 20. Eur J Cancer 1993; 29A(10): 1469-1475. [fulltext]
  • Murphy DS, McHardy P, Coutts J, Mallon EA, George WD, Kaye SB, Brown R, Keith WN: Interphase cytogenetic analysis of erbB2 and topoIIa co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ. Int J Cancer 1995; 64: 18-26. [fulltext]
  • Nitiss JL, Beck WT: Antitopoisomerase drug action and resistance. Europ J Cancer 1996; 32A(6): 958-966. [fulltext]
  • Shimizu T, Pommier Y: DNA fragmentation induced by protease activation in p53-null human leukemia HL60 cells undergoing apoptosis following treatment with the topoisomerase I inhibitor camptothecin: cell-free system studies. Exp Cell Res 1996; 226: 292-301. [fulltext]